Nido Biosciences develops precision medicines targeting severe neurological diseases by utilizing a functional genomics discovery platform based on human iPSC-derived neurons to identify novel therapeutic targets. Their lead candidate, NIDO-361, aims to treat Spinal and Bulbar Muscular Atrophy (SBMA) by restoring healthy cell function disrupted by an X-linked genetic mutation in the androgen receptor gene.
Funding
$109M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BVFounders
Product
Problem
Many severe neurological diseases lack effective treatments, resulting in progressive loss of function and significantly impacting patients' daily lives. Current approaches often fail to address the underlying biology of these diseases, leaving a critical unmet need for precision medicines that restore healthy cell function.
Solution
Nido Biosciences develops precision medicines for severe neurological diseases by leveraging a functional genomics discovery platform based on human iPSC-derived neurons. This platform identifies novel therapeutic targets and enables the development of treatments that address the fundamental biology of disease. Their lead candidate, NIDO-361, is designed to treat Spinal and Bulbar Muscular Atrophy (SBMA) by restoring healthy cell function disrupted by a genetic mutation in the androgen receptor gene. Nido Bio is also pursuing programs targeting Amyotrophic Lateral Sclerosis (ALS), Rare Tauopathies, and Frontotemporal Dementia (FTD).
Target Audience
The primary target audience includes patients suffering from severe neurological diseases such as Spinal and Bulbar Muscular Atrophy (SBMA), Amyotrophic Lateral Sclerosis (ALS), Rare Tauopathies, and Frontotemporal Dementia (FTD).
Features
- Functional genomics discovery platform utilizing human iPSC-derived neurons
- Target identification through tailored screens for neurological diseases
- NIDO-361: a small molecule allosteric modulator of the androgen receptor for the treatment of SBMA
- Programs targeting ALS, Rare Tauopathies, and FTD
- Small molecule modulators designed to activate autophagy while inhibiting neuroinflammation and cell death